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Elevated leptin and decreased 
adiponectin independently predict 
the post-thrombotic syndrome in 
obese and non-obese patients
Sandra Mrozinska  1,2, Joanna Cieslik  3, Elżbieta Broniatowska4 & Anetta Undas5,6
Post-thrombotic syndrome (PTS) is a common complication of deep vein thrombosis (DVT). Little 
is known about the involvement of adipokines in the pathogenesis of DVT. We evaluated whether 
adipokines can predict PTS. In a prospective cohort study, 320 DVT patients aged 70 years or less were 
enrolled. Serum adiponectin, leptin and resistin levels were measured three months since the index 
first-ever DVT. After 2 years’ follow-up PTS was diagnosed in 83 of 309 available patients (26.9%) 
who had 13.9% lower adiponectin and 16% higher leptin levels compared with the remainder (both 
p < 0.0001). No PTS-associated differences in C-reactive protein, fibrinogen, D-dimer, plasminogen 
activator inhibitor-1 and resistin were observed. The multivariable logistic regression adjusted for age, 
sex, obesity and tissue plasminogen activator (tPa) showed that lower adiponectin (odds ratio [OR], 
0.42; 95% confidence interval [CI], 0.31–0.56) and higher leptin levels (OR, 1.49; 95% CI, 1.31–1.69) 
are independent predictors for PTS. Obesity-stratified logistic regression analysis confirmed that 
lower adiponectin (OR, 0.49; 95% CI, 0.38–0.64) and higher leptin (OR, 1.41; 95% Cl, 1.25–1.58) levels 
predicted PTS. Our findings showed that lower adiponectin and higher leptin measured 3 months 
after DVT, regardless of obesity, can independently predict PTS, which suggests novel links between 
adipokines and thrombosis.
Post-thrombotic syndrome (PTS) is a common complication of deep vein thrombosis (DVT)1, that manifests 
as pain, a sensation of swelling, cramps, heaviness, edema, redness and telangiectasia in the lower limbs1,2. PTS 
develops in 20–50% patients after DVT2–4 and increases a risk of recurrent venous thromboembolism (VTE)5. 
Other factors predisposing to VTE recurrence include proximal unprovoked DVT, first symptomatic pulmonary 
embolism (PE), severe thrombophilia, and several emerging biomarkers6–9. The well-established risk factors for 
PTS are obesity, proximal DVT, and ipsilateral DVT recurrence10.
There is evidence that inflammation is involved in the pathogenesis of PTS11,12. Elevated inflammatory 
markers, including interleukin (IL)-10, C-reactive protein (CRP), and IL-6, have been reported in patients with 
PTS11–13.
Obesity, a risk factor for PTS2,10,14,15, is associated with a pro-inflammatory and prothrombotic state16,17. The 
adipose tissue secretes several hormones and cytokines known as adipokines, including IL-6, tumor necrosis 
factor-alpha (TNF-α), leptin, adiponectin, plasminogen activator inhibitor 1 (PAI-1), resistin, and others18,19. 
Adiponectin has been reported to have antithrombotic properties, while leptin is considered to have a prothrom-
botic effect20. In vitro studies showed that leptin promoted platelet aggregation21 and enhanced PAI-1, but not 
tissue-type plasminogen activator (tPa) expression in endothelial cells22. Animal studies showed that leptin is 
associated with venous thrombosis and PE23, while adiponectin decreased platelet aggregation by promoting 
endothelial nitric oxide and attenuate oxidative/nitrative stress24. Lower adiponectin levels were observed among 
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patients with confirmed PE25. Allison et al.26 reported that adipokines, i.e. resistin, leptin, TNF-α, are associated, 
independently of obesity and waist circumstance, with chronic venous disease.
To our knowledge, there have been no reports exploring the association between adipokines and PTS. Given 
links of obesity to PTS2,10,14,15 and experimental data on the impact of adipokines on prothrombotic mechanisms 
in various models21–26, we conducted a prospective cohort study to assess a predictive value of resistin, adiponec-
tin and leptin in the PTS development.
Methods
Patients. We screened 368 consecutive adult patients aged 70 years or less, after first-ever DVT alone or com-
bined with PE. We measured adipokines levels in one point time, 3 months since DVT and assessed the presence 
of PTS after a 2 years’ follow-up. The patients were referred to the outpatient clinic for further laboratory work-up 
between October 2008 and June 2012. The subgroup of this population was described in detail in our previous 
paper27. The diagnosis of DVT was established by a positive finding of color duplex sonography (visualization of 
an intraluminal thrombus in calf, popliteal, femoral, or iliac veins). The diagnosis of PE was based on the pres-
ence of typical symptoms and positive results of high resolution spiral computed tomography (CT), at least one 
subsegmental filling defect.
The exclusion criteria and flow chart of the study design can be found in Supplementary Fig. 1.
All patients received anticoagulant therapy with unfractionated or low-molecular-weight heparins, subse-
quently vitamin K antagonists (VKA) were implemented. The duration of the treatment was 3 months or more 
in patients with provoked VTE, or 6 months or longer in patients with unprovoked VTE at the discretion of the 
treating physicians. Compression stockings class II or hosiery were prescribed to all patients for 6–24 months at 
the time of DVT diagnosis.
Unprovoked (idiopathic) VTE episode was defined as not having surgery requiring general anesthesia, major 
trauma, plaster cast or hospitalization in the last month, taking oral contraceptives, pregnancy or delivery in the 
last 3 months. A proximal DVT event was defined as thrombosis in the popliteal vein, including the trifurcation, 
femoral or iliac veins. Positive family history of VTE was defined as a history of documented VTE in at least one 
first degree relative. Obesity was defined as BMI ≥30 kg m−2.
The study was approved by the Jagiellonian University Bioethical Committee. All the patients gave written 
informed consent to participate in the study. The research was conducted in accordance with the Declaration of 
Helsinki.
Follow-up. The primary endpoint of the study was the presence of PTS after a 2 years’ follow-up based on the 
Villalta scale1. The study participants were examined after 18 to 24 months at the clinic. The subjects suspected 
of PTS were re-evaluated on the second visit after 3 to 6 months and the final score was analyzed. Evaluation 
was performed by one physician, blinded to the results of laboratory investigations or duplex ultrasound. The 
Villalta scale contains eleven symptoms and clinical signs: pain, cramps, heaviness, paresthesia, pruritus, pretibial 
edema, skin induration, hyperpigmentation, redness, venous ectasia, pain on calf compression and venous ulcer. 
The points are given from 0 to 3 depending on the severity of the above features. PTS was diagnosed based on 5 
points or more on two consecutive visits, at least 3 months apart. The severity of PTS was classified as mild (5 to 9 
points), moderate (10 to 14 points) or severe (>14 points)1.
VTE recurrences were recorded and confirmed with imaging, i.e. color duplex sonography for DVT and 
high resolution spiral CT for PE. In cases of suspected DVT recurrence in the same leg as the index event, 
non-compressibility of a previously compressible venous segment or an increase of at least 4 mm in the residual 
diameters were applied to confirm the diagnosis. Following a recurrent thromboembolic event patients received a 
low-molecular-weight heparin, usually enoxaparin, at therapeutic doses with the subsequent VKA administration 
and the evaluation for PTS was performed 2 years after the index DVT.
We collected data on the medications used, especially the duration of VKA anticoagulation; subjects who 
stopped anticoagulation, in particular those after unprovoked events, were advised to use sulodexide 250–500 mg 
bid and/or aspirin 75–100 mg once daily. None of the patients was treated with direct oral anticoagulants during 
follow-up. Patients who declared regular use of compression therapy for a period of 6–24 months (usually with a 
6–8 weeks’ interruption in the June-August weeks) were recorded.
Laboratory investigation. After 3 months (±2 weeks) of anticoagulant therapy after DVT, fasting blood 
samples were taken from an antecubital vein with minimal stasis between 8.00 and 11.00 AM as described pre-
viously27. Patients treated with VKA were switched to a low-molecular-weight heparin for 10–14 days before 
and blood samples were collected after 16–24 hours after the last injection, subsequently the anticoagulation 
with VKA was continued. High-sensitivity CRP was assessed using immunoturbidimetry (Roche Diagnostics, 
Mannheim, Germany). Fibrinogen was measured with the Clauss assay. Plasma D-dimer was determined with 
the Innovance D-dimer assay (Siemens, Marburg, Germany). Leptin, adiponectin and resistin were measured in 
serum with the Bio-Rad Luminex flow cytometry (Millepore, Billerica, MA, USA). Leptin, adiponectin and resis-
tin levels in age- and BMI- matched control subjects free of VTE (n = 47, 27 women, aged 26–64 years) assayed in 
our lab served as comparators for adipokines in the patient cohort.
PAI-1 and tPa antigens were determined in citrated plasma using immunoenzymatic assays (both American 
Diagnostica, Stamford, CT, USA). All patients were screened for thrombophilia as described28.
Plasma thrombogenic potential was assessed using calibrated automated thrombography (CAT) (Thrombinoscope 
BV, Maastricht, the Netherlands) in a 96-well plate fluorometer (Ascent Reader, Thermolab systems OY, Helsinki, 
Finland) at 37 °C according to the manufacturer’s instructions as described29. Briefly, 80 microliters of platelet poor 
plasma were diluted with 20 µL of a tissue factor-based activator (Diagnostica Stago, Asniéres, France) containing 
5 pmol/L recombinant tissue factor, 4 micromolar phosphatidylserine/phosphatidylcholine/phosphatidylethanolamine 
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vesicles, and 20 µL of FluCa solution (Hepes, pH 7.35, 100 nmol/L CaCl2, 60 mg/mL bovine albumin, and 2.5 mmol/L 
Z-Gly-Gly-Arg-amidometylcoumarin). The peak thrombin level was analyzed in duplicate. Intraassay variability 
was 6%.
Statistical analysis. The study was powered to have a 80% chance of detecting a difference in adiponectin 
levels using an alpha value of 0.05, based on the values of adiponectin presented in a previous study25. Taking into 
account that about 20% of patients develops PTS, in order to demonstrate such a difference or greater, at least 166 
patients were required in the control group and 42 patients in the PTS group. The Cohen’s effect size was 0.5. The 
calculations were performed using G* Power Version 3.0.1030.
The continuous variables are presented as mean ± standard deviation (or median and interquartile range) 
whereas the categorical and qualitative variables are expressed as the number (percentages). The normality of 
variable distribution was verified by the Shapiro-Wilk test. The Levene’s test was used to assess the equality of var-
iances. The parametric Student t-test was used for continuous variables if the criteria for normality and equality of 
variances were fulfilled. Otherwise the Mann-Whitney U or the Welch tests were performed. Categorical variables 
were compared between groups using the chi-square test or Fisher’s exact test. The Spearman’s rank correlation 
test was used to explore the association between two continuous variables. Both univariate and multivariable 
logistic regression models were calculated to establish the risk factors for PTS. The linear association of all contin-
uous predictors with PTS was assessed using Generalized Additive Models with the LOWESS curve smoothing 
method. Multivariable logistic model was fitted using backward stepwise regression. The Akaike information 
criterion (AIC) was applied to compare multivariable logistic regression models. The p-value < 0.25 was selected 
as the threshold for including variables in the multivariable logistic model. Moreover, potential and known 
confounders and risk factors (like age, sex, obesity/BMI, proximal DVT, ipsilateral recurrent DVT, tPa) were 
considered in the studied models. The C-statistic (i.e. area under the curve [AUC]) was used to assess whether 
adipokines contributed significantly to predictive ability of PTS. The determination of the better model was done 
by the pair-wise comparison of C-statistic values with Bonferroni correction (significance level of 0.017 was 
applied). The obesity-stratified regression model was studied in order to assess the predictive value of adipokines 
independently of obesity. The receiver operating characteristic (ROC) curves were calculated to determine the 
optimal cut-off levels of adipokines as predictors of PTS. The AUC was also analyzed. The p-values < 0.05 were 
considered statistically significant for two-sided tests. The calculations were performed using Statistica 12.5 soft-
ware (StatSoft Inc., Tulsa, Oklahoma, United States) and R package31.
Data Availability. The datasets analysed during the current study are available from the corresponding 
author on reasonable request.
Results
A total of 309 patients at a median age of 46 years were included in the final analysis (Table 1, Supplementary 
Fig. 1, Supplementary Table 1). The minimum age was 18 and the maximum age was 69 years. Eleven patients 
were lost to follow-up. Most of the patients had isolated, unprovoked DVT. As expected, obese subjects (n = 63, 
20.4%) had slightly higher leptin and lower adiponectin levels compared with those with BMI < 30 kg m−2 
(n = 246, 79.6%, Supplementary Table 2). There were no gender- or age-related differences in adipokines (data 
not shown).
We compared the DVT patient and controls matched for age and BMI, the former group had lower adiponec-
tin (14.9 [13.7–16.8] versus 18.6 [17.5–21.4] µg mL−1, p < 0.001) and higher leptin (27.5 [24.4–30.3] versus 15.3 
[14.2–17.2] ng mL−1, p < 0.001) levels, while there was no difference in resistin concentrations (14.9 [13.9–16.2] 
versus 14.7 [13.5–15.9] pg mL−1, p = 0.27), which is in line with the study by Allison et al.26.
Men with DVT who were younger than control men (45 [36–55] vs 55.5 [41–61] years; p = 0.01) had lower 
adiponectin (14.9 [13.6–17] vs 18.5 [17.7–20.5] µg mL−1) and higher leptin 27.4 [24.8–30.1] vs 15.1 [14.2–17.2] 
ng mL−1; all p < 0.001, respectively). Also women with DVT when compared with control women had lower adi-
ponectin (14.8 [13.7–16.6] vs 19.5 [17.5–21.5] µg mL−1) and higher leptin (27.7 [24.2–30.4] vs 15.4 [14.3–16.8] 
ng mL−1; p < 0.001, respectively) when analyzed separately.
Interestingly, patients with unprovoked DVT compared with those with provoked DVT had slightly higher 
leptin (27.9 [24.9–30.4] versus 26.9 [23.7–30] ng mL−1, p = 0.04), lower resistin (14.7 [13.7–15.9] versus 15.2 
[14.0–16.7] pg mL−1, p = 0.02), and tended to have lower adiponectin concentrations (14.7 [13.5–16.6] versus 15 
[13.9–16.9] µg mL−1, p = 0.06, respectively) despite similar BMI values in the two subgroups (26.1 [23.8–29.3] 
versus 26 [23.4–29.4] kg m−2, p = 0.72). Adipokines did not differ between patients with isolated DVT versus 
those with DVT combined with PE as well as between patients with proximal DVT versus distal DVT (data not 
shown).
Adiponectin was inversely correlated with leptin (r = −0.45, p < 0.0001). Resistin was weakly correlated with 
leptin (r = 0.13, p = 0.03), but not with adiponectin (p = 0.28). As expected, there was a positive association of 
BMI and leptin (r = 0.33, p < 0.0001) and a negative correlation with adiponectin (r = −0.52, p < 0.0001). Mean 
adipokines levels adjusted for age and gender across four BMI categories are shown in Fig. 1.
There were no associations between adipokines and peak thrombin, fibrinogen, CRP, and D-dimer. Resistin 
and leptin, but not adiponectin, were positively correlated with tPa (r = 0.32, p < 0.0001; and r = 0.17, p = 0.003) 
and PAI-1 antigens (r = 0.34, p < 0.0001; and r = 0.14, p = 0.014, respectively).
After 2 years’ follow-up PTS was diagnosed in 83 (26.9%) patients, including mild PTS in 37 (44.6%), moder-
ate PTS in 30 (36.1%), and severe PTS in 16 (19.3%) individuals. There were no leg ulcers among patients. There 
was no difference in age, sex and the duration of anticoagulant treatment between the PTS and non-PTS group. 
PTS was associated with slightly greater BMI, higher triglycerides and tPa levels (Table 1, Supplementary Table 1). 
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There were no differences in proportions of patients who discontinued anticoagulation after 3–6 months as well 
as after 6–12 months since DVT between the PTS and non-PTS groups (data not shown).
Patients who developed PTS had 13.9% lower adiponectin and 16% higher leptin levels measured 3 months 
after DVT when compared with those free of this complication, with no difference in resistin concentrations 
(Table 1). A similar trend was observed in non-obese patients, i.e.13.1% lower adiponectin (p < 0.001) and 20% 
higher leptin (p < 0.001) when compared individuals with PTS versus those without PTS. This was also true for 
Variable All patients (n = 309) No PTS (n = 226) PTS (n = 83) P value
Age, years 46 (36–54) 47 (37–53) 44 (33–56) 0.36
Male sex, n (%) 150 (48.5) 104 (46.0) 46 (55.4) 0.14
BMI, kg m−2 26.1 (23.7–29.4) 25.7 (23–29) 27.3 (25–29.8) 0.002
Obesity, n (%) 63 (20.4) 43 (19) 20 (24.1) 0.34
Duration of anticoagulation 
treatment, months 10 (7–12) 10 (7–12) 10 (7–12) 0.55
Clinical characteristics, n (%)
Unprovoked VTE 157 (50.8) 112 (49.6) 45 (54.2) 0.47
DVT alone 242 (78.3) 177 (78.3) 65 (78.3) 1.00
Localization of isolated DVT, n (%)
    proximal DVT 171 (55.3) 123 (54.4) 48 (57.8) 0.59
    distal DVT 71 (23) 54 (23.9) 17 (20.5) 0.53
PE + DVT 67 (21.7) 49 (21.7) 18 (21.7) 1.00
Proximal DVT 238 (77) 172 (76) 66 (79.5) 0.53
Family history of VTE 46 (14.9) 30 (13.3) 16 (19.3) 0.19
Compression therapy 211 (68.3) 158 (69.9) 53 (63.9) 0.31
Laboratory investigations
CRP, mg L−1 1.5 (0.9–2.3) 1.5 (0.9–2.2) 1.7 (0.9–2.3) 0.42
INR 0.98 (0.9–1.04) 0.98 (0.91–1.04) 0.97 (0.87–1.04) 0.14
Fibrinogen, g L−1 3.03 (2.53–3.86) 3.02 (2.52–3.81) 3.04 (2.53–4.04) 0.70
D-dimer, ng mL−1 279 (226–337) 277 (226–337) 287 (221–347) 0.89
tPa, ng mL−1 9.6 (7.2–11.4) 9.4 (6.9–11.2) 10.3 (8–11.9) 0.02
PAI-1, ng mL−1 11.2 (8.5–14.7) 11.1 (8.5–13.9) 11.9 (8.5–15.0) 0.18
Peak thrombin, nM 245.7 (210–291.1) 244.8 (210–292.5) 246.2 (210–286.4) 0.93
Adipokines
Adiponectin, µg mL−1 14.9 (13.7–16.8) 15.8 (14.2–17.7) 13.6 (12.5–14.7) <0.0001
Leptin, ng mL−1 27.5 (24.4–30.3) 26.2 (22.8–28.4) 30.4 (28.8–32.8) <0.0001
Resistin, pg mL−1 14.9 (13.9–16.2)* 14.8 (13.8–16.2)* 15.2 (14–16.5) 0.38
Table 1. Patient Characteristics. Values are given as mean ± standard deviation (SD), median (interquartile 
range) or number (percentage). PTS, post-thrombotic syndrome; BMI, body mass index; VTE, venous 
thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; CRP, C-reactive protein; INR, 
international normalized ratio; tPa, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor-1. 
*Data unavailable for one patient.
Figure 1. Mean adipokines levels (adiponectin, leptin, resistin) non-adjusted (black small boxes) and adjusted 
(grey small boxes) for sex and age across four body mass index categories. Boxes represent mean values, “whiskers” 
represent a 95% confidence interval (CI). The CIs in resistin levels are very narrow, so that are hardly visible.
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obese subjects with PTS, who had 17.4% lower adiponectin (p < 0.001) and 14.3% higher leptin (p < 0.001) com-
pared with those free of this complication.
In the whole cohort leptin and adiponectin were correlated with the Villalta score (r = 0.36, p < 0.0001, and 
r = −0.33, p < 0.0001, respectively, Fig. 2). In subjects diagnosed with PTS there were no such associations. There 
were no differences in adiponectin (13.6 [12.7–14.6] versus 13.3 [12.2–14.8] µg mL−1, p = 0.66), leptin (30.3 
[28.3–32.2] versus 32.4 [29.3–33.8] ng mL−1, p = 0.08) and resistin levels (15.2 [14–16.5] versus 15 [14.2–16.5] pg 
mL−1, p = 0.92) between the non-severe and severe PTS subgroups.
The presence of PTS was associated with higher BMI, higher leptin, and lower adiponectin levels (all p < 0.05; 
Table 2 and Supplementary Table 3). The multivariable logistic regression model adjusted for age, sex, obesity 
and tPa showed that higher leptin and lower adiponectin levels are independent predictors for PTS in this DVT 
patient cohort (Table 2). The C-statistic for this regression model was 0.9, whereas in the case of the same model 
without adipokines, it was 0.63 (p < 0.0001, for comparison of both models). In the model including BMI as a 
continuous variable instead of obesity with adjustment for age, sex, BMI and tPa, elevated leptin and decreased 
adiponectin also predicted PTS and the C-statistic was 0.9 (Supplementary Table 3). The C-statistic for the same 
model without adipokines was 0.68 (p < 0.0001, for comparison of both models).
Importantly, the obesity-stratified logistic regression analysis adjusted for age, sex and tPa also confirmed 
that lower adiponectin (OR, 0.49; 95% CI, 0.38–0.64) and higher leptin (OR, 1.41; 95% Cl, 1.25–1.58) levels were 
predictors for PTS (Supplementary Table 4).
Models including a single adipokine were built and also showed that lower adiponectin and higher leptin are 
risk factors for PTS independently of obesity (data not shown).The C-statistic for the model with only adiponec-
tin was 0.84 (p < 0.001, for the comparison with the model without adipokines), whereas C-statistic for the model 
with only leptin was 0.83 (p < 0.001, for the comparison with the model without adipokines).
ROC analysis showed moderate specificity for adiponectin and leptin to predict PTS development using opti-
mal cutoffs with AUC of 0.8 (95% confidence interval [CI], 0.75–0.85; cutoff, 12.8 µg mL−1) and 0.82 (95% CI, 0.77–
0.87; cutoff, 32.1 ng mL−1, respectively, Table 3 and Fig. 3). Univariate logistic regression for categorical variables 
based on optimal cut-offs showed that leptin >32.1 ng mL−1 and adiponectin ≤12.8 µg mL−1 are associated with 
PTS occurrence during follow-up (Supplementary Table 5). The multivariable logistic regression model adjusted 
for age, sex, obesity, and tPa showed that increased leptin (values >32.1 ng mL−1) and decreased adiponectin (val-
ues ≤12.8 µg mL−1) levels predicted PTS (Supplementary Table 5). The C-statistic for the model was 0.76.
Recurrent DVT was observed in 35 (11.3%) individuals during 2 years’ follow-up, including 17 cases during 
anticoagulation treatment. There was no difference between the PTS and non-PTS group regarding the recurrent 
VTE (Supplementary Table 6).
The analysis of the patients after exclusion of those with recurrent DVT during follow-up after adjustment 
for age, sex, obesity and tPa also showed that decreased adiponectin (OR, 0.44; 95% CI, 0.32–0.63) and increased 
leptin (OR, 1.46; 95% CI, 1.26–1.69) predicted PTS in patients free of VTE recurrences.
Discussion
This study is the first to show the association between adipokines and the development of PTS after a 2-years’ 
follow-up in a cohort of young and middle-aged DVT patients. We observed that elevated leptin and decreased 
adiponectin levels measured in one point time, 3 months since the first-ever DVT episode are independent pre-
dictors of PTS regardless of inflammatory state and obesity. Given the paucity of clinical data on the impact of 
circulating adipokines on thrombosis, our findings extend the current knowledge of adipokines in thrombosis 
in humans.
There are accumulating data largely derived from in vitro studies and animal models to show that adipokines 
are involved in thrombosis. It has been demonstrated that administration of leptin neutralizing antibodies 
was associated with protection from lethal venous thrombosis and PE23. A similar effect was observed in lep-
tin deficient ob/ob mice23. Dellas et al. showed that among 264 patients with acute PE lower leptin levels at 
admission predicted death, circulatory collapse with need for catecholamines, intubation or resuscitation, in a 
30-day follow-up32. No data regarding a prognostic value of leptin among DVT patients have been published 
yet. Adiponectin is suggested to have anti-aggregatory properties24,33. Patients with confirmed PE had lower adi-
ponectin compared with the control group25.
Figure 2. Correlations between the Villalta scores and two adipokines. The associations between variables 
measured 3 months since VTE in 309 patients - (A) adiponectin, (B) leptin and the Villalta score assessed after a 
two-year follow-up since venous thromboembolism (VTE) episodes.
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Our study expanded observations made by Allison et al.26 in 2010. They demonstrated that resistin, leptin, and 
TNF-α are associated, independently of obesity and waist circumstance, with chronic venous disease. However, 
in contrast to our study, the Villalta score was not used by Allison et al.26 and previous DVT was not presented 
in association with adipokines. In the former study, increased intra-abdominal pressure, and multiple inflam-
matory/metabolic effects of adipokines were postulated to contribute to venous disease26. We found that inflam-
matory mechanisms are rather unlikely to largely contribute to PTS, however, this issue requires further study.
Given strong links between body weight and adipokines, our findings are important since the predictive value 
of adiponectin and leptin for PTS remained significant after adjustment for BMI as well as obesity. Moreover, the 
obesity-stratified logistic regression analysis showed that lower adiponectin and higher leptin predict PTS sug-
gesting that their harmful effect is independent of obesity. Whether weight reduction lowers the risk of PTS also 
through changes in unfavorable adipokine profiles, deserves further investigation.
We did not notice differences in adipokines levels related to gender and age in our DVT cohort. However, 
there are inconclusive reports regarding age- and sex- related differences in adipokines, and this issue merits 
further investigagtion34,35.
Enhanced inflammation reflected by elevated CRP and IL-10 has been shown to be risk factor for developing 
PTS11,12. We failed to show higher CRP at 3 months in patients who developed PTS after 2 years since the index 
DVT. However, we excluded patients with CRP above 15 mg L−1. Roumen-Klappe et al. found a weak association 
between CRP and PTS diagnosed according to the Clinical Etiologic Anatomic Pathologic classification, and no 
Variable OR per
Univariate Multivariable*
OR (95% CI) P OR (95% CI) P
Age† 10 years 0.89 (0.72–1.10) 0.27
Male† No/Yes 1.46 (0.88–2.42) 0.14 1.83 (0.91–3.66) 0.09
Obesity† No/Yes 1.35 (0.74–2.47) 0.33 0.61 (0.26–1.42) 0.25
Duration of anticoagulation 
treatment 1 month 1.03 (0.96–1.10) 0.49
Smoking No/Yes 0.94 (0.56–1.60) 0.83
Unprovoked VTE No/Yes 1.21 (0.73–2.00) 0.47
Proximal DVT No/Yes 1.22 (0.66–2.25) 0.53
Recurrent DVT ipsilateral No/Yes 1.51 (0.58–3.92) 0.4
Family history of VTE No/Yes 1.56 (0.80–3.04) 0.19
Compression therapy No/Yes 0.76 (0.45–1.30) 0.31
Aspirin‡ No/Yes 0.71 (0.33–1.56) 0.39
Sulodexide‡ No/Yes 1.18 (0.55–2.50) 0.68
Statins No/Yes 1.08 (0.65–1.80) 0.76
Creatinine 1 µmol L−1 1.01 (0.99–1.03) 0.22
Glucose 1 mmol L−1 1.05 (0.73–1.52) 0.79
Triglycerides 1 mmol L−1 1.36 (0.94–1.97) 0.11
CRP 1 mg L−1 1.07 (0.90–1.27) 0.43
Fibrinogen 1 g L−1 1.08 (0.82–1.42) 0.59
D-dimer 100 ng mL−1 1.01 (0.78–1.31) 0.91
tPa† 1 ng mL−1 1.11 (1.02–1.21) 0.02 1.06 (0.95–1.2) 0.31
PAI-1 1 ng mL−1 1.04 (0.99–1.08) 0.08
Peak thrombin 10 nM 0.99 (0.96–1.03) 0.77
Adiponectin 1 µg mL−1 0.52 (0.43–0.64) <0.001 0.42 (0.31–0.56) <0.0001
Leptin 1 ng mL−1 1.41 (1.28–1.56) <0.001 1.49 (1.31–1.69) <0.0001
Resistin 1 pg mL−1 1.02 (0.92–1.12) 0.75
Table 2. The logistic Regression Model for Risk Factors of PTS. OR, odds ratio; CI, confidence intervals; other 
abbreviations see Table 1. *Multivariable model was fitted using backward stepwise regression. Adjusted for age. 





(95%CI) PPV (95%CI) NPV (95%CI)
LR positive 
(95%CI) OR (95%CI)
Adiponectin 12.8 µg mL−1 0.30 (0.21–0.41) 0.96 (0.92–0.98) 0.74 (0.56–0.87) 0.79 (0.74–0.84) 7.56 (3.68–15.53) 10.39 (4.60–23.48)
Leptin 32.1 ng mL−1 0.34 (0.24–0.45) 0.95 (0.91–0.97) 0.7 (0.53–0.83) 0.8 (0.74–0.84) 6.35 (3.39–11.9) 9.08 (4.34–19.00)
Table 3. Measures of Performance of Adipokines to Predict the PTS. Based on the optimal cut-off levels of 
adipokines as predictors of PTS that were determined based on the receiver operating characteristic (ROC) 
curves. PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio; other abbreviations 
see Tables 1 and 2.
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association with the Villalta-defined PTS36; the scale used in our report. Other studies, like ours, also did not find 
any relation between CRP levels and PTS development12. We cannot exclude that other inflammatory markers 
are better predictors of PTS, however, assessment of interleukins or adhesion molecules was beyond the scope of 
this study.
Mechanisms underlying an elevated risk of PTS in subjects with higher leptin and lower adiponectin are likely 
multifactorial20–26,32. In our study there was a weak positive correlation between leptin and PAI-1, which agrees 
with a recent study on healthy and hypertensive individuals37. We may hypothesize that hypofibrinolytic effects 
of disturbed adipokines profiles in circulating blood contribute to our observations. Given the data showing an 
increased risk of PTS in patients with prolonged clot lysis time27, the current findings might support the associ-
ation between hypofibrinolysis and PTS. Moreover, adipokines could be linked with chronic venous disease by 
their metabolic effect on insulin resistance involved in thrombosis38,39.
Several study limitations should be acknowledged. First, our study was relatively small but adequately pow-
ered to show an expected rate of PTS during follow-up similar to that reported in the literature2,14. We studied 
relatively young DVT patients, so the current results cannot be easily extrapolated to all DVT patients, especially 
to the elderly with several comorbidities. Laboratory variables including adipokines were measured in a single 
point time, therefore changes with time in some of them cannot be excluded for example due to weight increase or 
decrease. However, most of the patients reported their weight difference at 2 years at a level of about 5% compared 
with the initial values. Some patients stopped anticoagulation after a few months even if they suffered from prox-
imal unprovoked DVT, so it is unclear whether prolonged treatment or the use of direct oral anticoagulants since 
the diagnosis of DVT may affect the risk of PTS and its association with adipokines40. Elucidation of the precise 
molecular mechanisms behind the observed impact of adipokines on PTS was beyond the scope of the present 
study and should be explored in the future.
In conclusion, our study showed that higher leptin and lower adiponectin predicted PTS in relatively young 
DVT patients regardless of obesity. This suggests previously unknown links of adipokines and thrombosis and its 
complications. If future studies confirm a predictive value of elevated leptin and decreased adiponectin for PTS it 
could help identify patients at increased risk of PTS development, who need an individualized treatment.
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